This invention relates to a series of new pro-drug nitric oxide donor compositions. Nitric oxide (NO) is a crucial signaling and regulating molecule with wide-ranging functions in the cardiovascular, nervous and immune systems, such as blood vessel relaxation, neurotransmission and pathogen suppression. Delivery of supplementary NO through NO donor hybrid compounds is thought to be an attractive therapeutic option to prevent disease progression. These drugs have shown anti-cancer and anti-viral effects in vitro and may also have applications as vasorelaxants antithrombotics or cytostatic or genotoxic compounds.
The NO donor compounds covering in this WSU invention are sugar-modified linsidomines, also known as 3-morpholinosydnonimine and commonly referred to as SIN-1. Several novel sugar modified SIN-1 compounds, pharmaceutical compositions and methods of using them to deliver NO to a targeted cell by taking advantage of the role of carbohydrates in cell recognition and internalization processes are provided. One example structure is shown below.
Using these compounds site-specific and controlled-release of nitric oxide can be achieved and thus may be useful for regulating many physiological processes.
Issued US Patent: 6,867,194
Reference paper: “New Glycosidase Activated Nitric Oxide Donors: Glycose and 3-Morphorlinosydnonimine Conjugates” J. Org. Chem. 2005, 70, 3518-3524